.png){kind=icon}
Return
Soft Tissue Sarcoma, Version 2.2022
.png){kind=icon}
OA
AI
DOI：10.6004/jnccn.2022.0035.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Soft tissue sarcomas (STS) are rare malignancies of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic char-acteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues. The evaluation and treatment of pa-tients with STS requires a multidisciplinary team with demonstrated expertise in the management of these tumors. The complete NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Soft Tissue Sarcoma provide recommendations for the diagnosis, eval-uation, and treatment of extremity/superficial trunk/head and neck STS, as well as retroperitoneal/intra-abdominal STS, desmoid tumors, and rhabdomyosarcoma. This portion of the NCCN Guide-lines discusses general principles for the diagnosis and treatment of retroperitoneal/intra-abdominal STS, outlines treatment recom-mendations, and reviews the evidence to support the guidelines recommendations. J Natl Compr Canc Netw 2022;20(7):815???833 doi: 10.6004/jnccn.2022.0035
Keywords:
RANDOMIZED PHASE-II
PREOPERATIVE RADIATION-THERAPY
DOXORUBICIN PLUS IFOSFAMIDE
ELECTRON-BEAM RADIOTHERAPY
HIGH-RISK EXTREMITY
NEOADJUVANT CHEMOTHERAPY
EUROPEAN-ORGANIZATION
RETROPERITONEAL SARCOMA
ADJUVANT CHEMOTHERAPY
1ST-LINE TREATMENT
Journal
J
IF:
16.4
Papers:
2.8K
Citations:
1.5W
Organization
View more organizations
Cited Papers
ShareSaveDocetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: A retrospective analysis
OAAI
OAAIShareSaveShareSaveREGOSARC: Regorafenib Versus Placebo in Doxorubicin-Refractory Soft-Tissue Sarcoma-A Quality-Adjusted Time Without Symptoms of Progression or Toxicity Analysis.png)
CANCEROAAI
CANCERIF5.1
OAAIShareSaveShareSave View more